Clinical Trial Update: Sunitinib in Sarcomas of the Central Nervous System [Phase 2]

View source ↗

Summary

Phase 2 trial of sunitinib in gliosarcoma and central nervous system sarcoma was terminated; results posted in 2022.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Central Nervous System Sarcoma
• Gliosarcoma

Drugs mentioned

• Sunitinib (sunitinib)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Gliosarcoma, Central Nervous System Sarcoma | Phase 2 | Status: TERMINATED | Results posted: 2022-04-19